dr serzan on the potential of botensilimab/balstilimab to address unmet needs in rcc
Published 3 months ago • 96 plays • Length 0:59Download video MP4
Download video MP3
Similar videos
-
4:48
unmet needs in rcc
-
1:08
dr. mcgregor on unmet needs in non-clear cell rcc
-
2:15
dr. shuch on the impact of the surtime trial in advanced rcc
-
1:13
dr. mckay on unmet needs for rcc
-
1:19
dr. le on research needed to address unmet needs in mcrc
-
1:34
unmet needs in the treatment of renal cell carcinoma
-
7:08
unmet needs in kidney cancer
-
1:25
dr. hsieh on unmet needs of rare kidney cancer variants
-
22:34
aviv regev: "cell atlases as roadmaps in caner immunology"
-
24:55
single cell transcriptomics - analysis tools and quality control (3 of 10)
-
14:59
the origins of covid 19 – what scientific research tells us
-
4:49
unmet needs in the adjuvant setting for renal cell carcinoma
-
1:05
dr. shuch on biology of non-clear cell rcc
-
1:52
dr. powles on monitoring immunotherapy effects in patients with rcc
-
4:15
the unmet needs of kidney cancer treatment
-
1:14
dr. jonasch on single-agent pembrolizumab in non-clear cell rcc
-
1:10
dr. mcdermott on the promise of pembrolizumab in non-clear cell rcc
-
1:10
dr. jonasch on molecular understanding of clear cell rcc
-
0:31
unmet needs in the use of circulating tumor cells for prostate cancer
-
1:21
dr. uzzo on unmet needs in kidney cancer
-
5:28
understanding the biology of kidney cancer
-
5:27
non-clear cell histologies in rcc